

# Adipose Mesenchymal Stem Cells Combined with Platelet Rich Plasma Accelerate Diabetic Wound Healing by Modulating Notch Pathway

**Nesrine Ebrahim**

Benha University Faculty of Medicine

**Arigue Dessouky**

Zagazig University

**Ola Mostafa**

Benha University

**Mohamed Yousef**

Benha University

**Yasmin Seleem**

Benha University

**Eman El Gebaly**

Benha University

**Mona Allam**

Benha University

**Ayman Farid**

Benha University

**Bayan Saffaf**

Future University in Egypt

**Dina Sabry**

Cairo University

**Amira Hassouna**

AUT - City Campus: Auckland University of Technology

**Ahmed Nawar**

Benha University

**Ahmed Shoulah**

Benha University

**Sami Abdalla**

Almaarefa College College of Medicine

**Mohamed El-Sherbiny**

Almaarefa College College of Medicine

**Nehal Elsherbiny** (✉ [drnehal@hotmail.com](mailto:drnehal@hotmail.com))

**Rabab Salim**

Benha University

---

## Research

**Keywords:** Diabetic wound, Adipose-mesenchymal stem cells, PRP, Notch pathway

**Posted Date:** April 2nd, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-372049/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Stem Cell Research & Therapy on July 13th, 2021. See the published version at <https://doi.org/10.1186/s13287-021-02454-y>.

# Abstract

**Background** Diabetic foot ulceration is a serious chronic complication of diabetes mellitus characterized by high disability, mortality and morbidity. Platelet-rich plasma (PRP) has been widely used for diabetic wound healing due to its high content of growth factors. However, its application is limited due to rapid degradation of growth factors. The present study aimed to evaluate the efficacy of combined adipose derived mesenchymal stem cells (ADSCs) and PRP therapy in promoting diabetic wound healing in relation to the Notch signaling pathway.

**Methods** Albino rats were allocated into 6 groups (control, sham, diabetic, PRP-treated, ADSCs-treated and PRP+ADSCs-treated groups). The effect of individual and combined therapy was evaluated by assessing wound closure rate, epidermal thickness, dermal collagen and angiogenesis. Moreover, gene and protein expression of key elements of Notch signaling pathway (Notch1, Delta like canonical Notch ligand 4 (DLL4), Hairy Enhancer of Split-1 (Hes1), Hey1, Jagged-1), gene expression of angiogenic marker (Vascular endothelial growth factor & stromal cell-derived factor 1) and epidermal stem cells (EPSCs) related gene ( $\beta$ 1 Integrin) were assessed.

**Results** Our data showed a strong wound-healing effect of PRP+ADSCs compared to their individual use after 7 and 14 days. Combined therapy caused marked increase in area percentage of collagen, epidermal thickness and angiogenesis. Moreover, Notch signaling was significantly down-regulated, EPSCs proliferation and recruitment was enhanced compared to other treated groups and diabetic group.

**Conclusions** These data demonstrated that PRP and ADSCs combined therapy significantly accelerated healing of diabetic wounds induced experimentally in rats via modulating Notch pathway, promoting angiogenesis and EPSCs proliferation.

## Introduction

Diabetes mellitus (DM) is a worldwide health problem affecting approximately 9.3% of the global population with its prevalence expected to rise by 25% in 2030 and 51% in 2045 (1). Diabetic foot ulceration (DFU) is one of the most common chronic diabetic complications leading to significant medical, economic, and social burdens. It is estimated that every 30 seconds, a complicated diabetic lower limb is lost worldwide as 15% to 25% of diabetic patients have a risk to develop a foot ulcer throughout their whole lifetime (2).

The strong regenerative & healing capabilities of skin are intimately linked to the existence of skin stem cells. The skin stem cells (predominantly epidermal stem cells (EPSCs) and hair follicle stem cells) are considered as important sources of cells for skin healing, regeneration, and metabolism and are located in the basal layer of the epidermis and also, in the hair follicle bulge which contains the most potent EPSCs (3). Typically, the more the remaining skin stem cells upon the wound surface, the particularly faster the curing rate, and the particularly less the scar formation. Normal cutaneous tissue has a diversity of stem cells with multipotent potentiality leading to, theoretically, any wound can easily rely on

skin stem cells to reach physiological repair. Nevertheless, in profound skin wounds, the remaining skin stem cells cannot experience normal differentiation capacity and complete the anatomical structure and functional skin repair according to the preprogrammed pathways. Therefore, the healing progression may be disrupted, ultimately developing scar tissue devoid of hair follicle and sweat glands (4). This indicates that the process of wound healing is associated with interaction among cells, complex regulation of the extracellular matrix, and various paracrine elements (5).

Provided the complexity of the multifactorial and multicellular processes of wound healing, it is believable that a therapeutic approach targeting different signaling pathways that control cellular processes significant for wound healing would likely serve as a considerable solution for DFU therapy. Notch signaling pathway is an evolutionarily preserved signaling mechanism with an extremely pleiotropic action. Notch signaling is essential for cell-fate determination. Besides, it also plays a critical role in regulating proliferation, angiogenesis, and apoptosis/survival, processes that are intensely disturbed in diabetic wounds (6). Notch signaling is actually a cell-cell interaction mechanism triggered as a result of the interaction between membrane-bound Notch receptors (Notch 1–4) and their particular ligands (Delta-like 1, 3, 4, and Jagged 1–2) on juxtaposed cells. This interaction induces  $\gamma$ -secretase-mediated cleavage and translocation of the Notch intracellular domain (ICD) into the nucleus, where it forms a transcriptional activation complex inducing the expression of downstream target genes, such as Hairy Enhancer of Split-1 (Hes1) and Hey1 (7). This signaling pathway performs essential tasks during development and throughout the regulation of adult tissue homeostasis. Besides, it plays a vital role in the postnatal physiology of the skin as well as in normal wound healing through the positive regulation of cell migration, angiogenesis, and inflammation (8).

Several innovative treatment options intended for DFU management have been discovered, like bioengineered skin substitutes, negative pressure dressings, and hyperbaric oxygen therapy. Nevertheless, the typically effective therapies are remaining inadequate. Therefore, it is essential to use more successful and efficient therapies like the use of autologous biologics, such as mesenchymal stem cell (MSC)-based therapies and platelet-rich plasma (PRP), which hold considerable promise to improve tissue regeneration in addition to chronic wound care management strategies (9). PRP can be acquired throughout an autologous manner, via centrifugation of the patient's blood leading to a plasma fraction with a platelet concentration greater than that of the circulating blood. The therapeutic properties of PRP are mostly endorsed to the release of platelet growth factors after its activation. These group of growth factors includes epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF-1, IGF2) which are recognized to favor tissue regeneration (10). On the other hand, adipose derived MSCs are adult multipotent stem cells with self-renewal potentiality, which can differentiate directly into different lineages and secrete paracrine elements starting the process of tissue regeneration. The plentiful supply of adipose tissue, simple isolation procedure, wide proliferative capabilities *ex vivo*, besides their capacity to secrete pro-angiogenic growth factors made them an ideal cell type to be used as a new therapy for the treatment of non-healed wounds. Moreover, the MSC secretome initiates healing simply by inducing a shift from pro-inflammatory to anti-inflammatory cytokine production at the injury site (11).

In the present study, we aimed to evaluate the therapeutic efficiency of PRP and ADSCs both individually and in combination in diabetic wound healing. Furthermore, we investigated the role of Notch signaling pathway in controlling the wound healing.

## Materials And Methods

### Experimental Animals

Adult male albino rats (180–200 g), 6 weeks of age, were purchased from the Experimental Animal Unit, Faculty of Veterinary Medicine, Benha University, Egypt. The rats were bred and maintained in an air-conditioned animal house under specific pathogen-free conditions. All animals were housed in clean cages and given a standard diet and clean water *ad libitum*. The rats were subjected to a normal light/dark cycle (12-h light-dark cycle starting at 8:00 AM) and room temperature ( $23 \pm 3$  °C) and allowed free access to chow and water. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH publication No. 85–23, revised 2011). All protocols were approved by the institutional review board for animal experiments of the Faculty of Medicine, Benha University, Egypt (BUFM 3 January 2018).

### Adipose Derived Stem Cell (ADSCs) Preparation

Adipose tissues from the abdominal wall of rats were obtained and then placed into a labeled sterile tube containing 15 mL of a phosphate buffered solution (PBS; Gibco/Invitrogen, Grand Island, NY, USA). Enzymatic digestion was performed using 0.075% collagenase II (SERVA Electrophoresis GmbH, Heidelberg, Germany) in Hank's Balanced Salt Solution for 60 min at 37 °C with shaking. Digested tissue was filtered and centrifuged, and erythrocytes were removed by treatment with an erythrocyte lysis buffer. The cells were transferred to tissue culture flasks with Dulbecco Modified Eagle Medium (DMEM, Gibco/BRL, Grand Island, New York, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco/BRL) and after an attachment period of 24 h, non-adherent cells were removed by a PBS wash. Attached cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin (Gibco/BRL), and 1.25 mg/L amphotericin B (Gibco/BRL), and expanded *in vitro*. At 80–90% confluence, cultures were washed twice with PBS and the cells were trypsinized with 0.25% trypsin in 1 mM EDTA (Gibco/BRL) for 5 min at 37 °C. After centrifugation, cells were resuspended in serum-supplemented medium and incubated in 50 cm<sup>2</sup> culture flask (Falcon). The resulting cultures were referred to as first-passage cultures and expanded *in vitro* until passage three (12).

### Labeling stem cells with Green Fluorescent Protein (GFP)

ADSCs were transfected with non-integrating plasmids containing GFP (addgene, pET His6 GFP TEV LIC cloning vector (1GFP); (Plasmid #29663). One day before transfection,  $5 \times 10^5$  cultured cells were plated in 1 ml complete growth medium and ADSCs transfected with a single plasmid using the Nucleofector kit (Lonza, Verviers, Belgium) according to the manufacturer's instructions (13). ADSCs labeled with GFP

were observed using a fluorescence microscope (Leica Microsystems CMS GmbH, Ernst-Leitz-Straße, Wetzlar, D-35578, Germany).

### **Immunophenotypic Characterization of Differentiated ADSCs**

ADSCs were initially characterized by their adhesiveness, fusiform morphology, and by detection of established surface markers of rat ADSCs by flow cytometry. Following isolation ADSCs were passaged, viable cell counts established, and aliquoted individually at  $1 \times 10^6$  cells/mL per tube. ADSCs were then incubated with 10  $\mu$ L of directly conjugated monoclonal antibodies; CD45 PE (rabbit monoclonal; [EP322Y] (ab200315), CD90 PE (mouse monoclonal Antibody (HIS51), bioscience, # 14-0900-81) and CD 105 PE (rabbit polyclonal antibody, CENTER E395; SAB1306487 Sigma Aldrich) at 4 °C in the dark for 20 minutes; matched isotype controls were included for control purposes. Following incubation, 2 mL of PBS containing 2% FCS solution was added to each tube followed by centrifugation for 5 min at 2500 rpm, discarding of the supernatant, and resuspending in 500  $\mu$ L PBS containing 2% FCS. Cell analysis was performed using CYTOMICS FC 500 Flow Cytometer (Beckman Coulter, Brea, CA, USA) and CXP software version 2.2 (14).

### **In vitro adipogenic, osteogenic and chondrogenic differentiation of ADSCs**

ADSCs were tested for their ability to undergo tri-lineage differentiation into adipocytes, osteoblasts, and chondrocytes. Passage 4 MSCs at a density of  $5 \times 10^3$  cells/cm<sup>2</sup> were seeded into precoated cover glass situated within six-well plates and induced for 3 weeks with either adipogenic (HUXMA-90031; Cyagen Biosciences Inc., Guangzhou, China), osteogenic (#HUXMA-90021; Cyagen Biosciences Inc.), or chondrogenic (#HUXMA-90041; Cyagen Biosciences Inc.) differentiation media, respectively. The cells were then fixed in 10 % formalin and stained with either Oil Red O, Alizarin red, or Alcian blue according to standard procedures (15).

### **Isolation of human platelet-rich plasma (PRP)**

Whole blood was collected from rats into acid citrate dextrose solution A (ACD-A) anticoagulant at a ratio of 1 mL ACD-A: 9 mL blood. To separate platelets from erythrocytes and leukocytes in plasma, 40 mL of this mixture was put into a 50-mL centrifuge tube and centrifuged at  $160 \times g$  for 10 min, and then the separated plasma containing platelets was transferred to a new centrifuge tube and centrifuged at  $250 \times g$  for another 15 min. Most of the supernatant plasma was discarded, before the platelet pellet was resuspended in the residual plasma to obtain 4 mL PRP, then activated with 10% CaCl<sub>2</sub> to become PRP gel to prevent its leakage from the wound (16).

### **Induction of DM**

Type I diabetes was induced in overnight fasted rats by a single intraperitoneal (IP) injection of freshly prepared Streptozotocin (STZ powder was obtained from Sigma-Aldrich Chemical Co., St. Louis, MO, USA; 60 mg/kg, dissolved in 0.1M cold citrate buffer, pH 4.5). After STZ injection, rats acquired drinking water

containing sucrose (15 g/L) for 48 h, to lessen the early death due to insulin discharge from partially injured pancreatic islets. Seventy-two hours later, rats were checked for hyperglycemia, and those with fasting blood sugar more than 250 mg/dL were included in the study. Diabetic rats received long-acting insulin (2–4 U/rat) via subcutaneous injection to maintain blood glucose levels in a desirable range (350 mg/dL) and to avoid subsequent development of ketonuria (17). Animals were maintained in a diabetic state for 6 weeks before the start of the wound-healing experiment.

## Wound Model

The Galiano's murine healing model was used (18) as this model minimizes rodent wound contractions and therefore mimics the wound healing processes occurring in humans including granulation tissue formation and reepithelialization. Rats were anesthetized with isoflurane gas (SEDICO, Egypt) inhalation (2.5% in 500 ml/min of air), and surgeries were performed under standard sterile conditions. Two circular, full-thickness 5mm diameter cutaneous wounds were inflicted on the back of each rat, and sterile donut-shaped silicone splints with a diameter two times of the wound were fixed to the surrounding wound edge with an adhesive film (3M™ Steri-Strip™ Skin Closures, 3M Science, Egypt) and interrupted 6-0 silk thread sutures to prevent skin retraction. The wounds were then covered with semi occlusive dressing (3M Tegaderm®, Egypt). During all the experiments, rats daily received intraperitoneal injection of buprenorphine (0.1 mg/kg/day).

## Wound Closure Analysis

Wound closures were blinded quantified through the measure of the wound reepithelialization at day 3, day 7, day 10 and day 14 post-surgery, through a macroscopic analysis of the lesions on the back of rats. A disposable 10-centimeter medical paper wound measuring ruler was used to measure the wound size. The wound closure rate at day X postsurgery was calculated as the percentage of the wound area at day X compared with that postoperative day 0 (9).

## Experimental Design and Treatment Protocol

The experimental design is shown in **Figure 1**. Ninety-eight male rats were randomly divided into six groups as follows:

**Group I (control group; n = 21):** Rats were fed a regular chow diet for 6 weeks. The rats were divided equally into three subgroups of 7 rats each:

Subgroup Ia: The rats were left without any intervention.

Subgroup Ib: The rats were injected intraperitoneal with a single dose of 0.25 mL/kg body weight sodium citrate buffer (vehicle for STZ).

Subgroup Ic: Rats were injected with 100 µl saline solution + CaCl<sub>2</sub> on the back of each rat.

Subgroup Id: Rats were injected with sterile phosphate-buffered saline solution on the back of each rat.

**Group II (Sham operation group; n = 14):** Rats were fed a regular chow diet for 6 weeks, then the wound was inflicted at the back of each rat and immediately after injury the wound base & edges were injected with 100 µl saline.

**Group III (Diabetic group; n=14):** After six weeks of DM induction, the wound was inflicted on the back of each rat and immediately after injury the wound base & edges were injected with 100 µl saline.

**Group IV (DM+PRP group; n= 14):** After six weeks of DM induction, the wound was inflicted on the back of each rat and immediately after that the wound base & edges were injected with 4 mL PRP activated with 10% CaCl<sub>2</sub>.

**Group V (DM+ADSCs group; n= 14):** After six weeks of DM induction, the wound was inflicted on the back of each rat and immediately after that the wound base & edges were injected with 100 µl of saline solution containing  $2 \times 10^6$  ADSCs.

**Group VI: (DM+ADSCs +PRP group; n= 14):** After six weeks of DM induction, the wound was inflicted on the back of each rat and immediately after that the wound base & edges were injected with 100 µl of saline solution containing  $2 \times 10^6$  ADSCs- in combination with 4 mL PRP activated with 10% CaCl<sub>2</sub>.

## Sampling

Rats in each group (except the control group) were equally subdivided into two subgroups (a & b) as follow: Rats in subgroup **a** were sacrificed after 7 days of wound infliction to assess the inflammatory phase of wound healing while rats in subgroup **b** were sacrificed after 14 days of wound induction to assess the proliferative phase of wound healing. In each subgroup the samples were taken from the wound site of the ulcerative tissue.

Half of the skin tissues were collected from rat to be evaluated by light microscopy with hematoxylin and eosin (H&E) and Masson's trichrome staining. An immunohistochemical evaluation for PCNA and CD31 were also performed. The other half of skin fresh tissue specimens were kept frozen at -80 °C for later quantitative real-time polymerase chain reaction (qRT-PCR) to assess the gene expression of Notch1, Dll4, Jag1, Hes1, Hey1, VEGF, SDF-1&EPSCm (β1 Integrin). Western blot analysis was also performed to assess the protein expression of Notch 1, Jag1 and Hes1.

## Gene expression profile

Total RNA was extracted from the skin specimens of treated and control rats using TRIzol (Invitrogen) according to the manufacturer's instructions. The concentration and purity of extracted RNA were measured by the Nano-Drop 2000C spectrophotometer (Thermo Scientific, USA). At absorbance ratio A260/A280, RNA purity for all samples was > 1.9. The integrity of RNA was verified on 2% agarose gel using a gel electrophoresis image (Gel Doc. BioRad) (19). Complementary DNA (cDNA) was synthesized for the target genes using SensiFast cDNA synthesis kits (Sigma Bioline, UK) according to the manufacturer's instruction using a T100 Thermal Cycler (Bio-Rad, USA).

Quantitative PCR was performed using Maxima SYBR Green/ROX qPCR master mix (2x) (Thermo Scientific, USA) (20). Primer pairs for selected target and reference genes (Notch 1, Dll4, Hes1, Hey1, Jag1, VEGF, SDF1, EPSCm and GAPDH) were purchased from Genwez (New Jersey, USA) (**Table 1**). Each PCR reaction consisted of 500 ng per reaction of cDNA (except for NTC and cDNA control), 12.5 µl Maxima SYBR Green qPCR Master Mix (Maxima SYBR Green qPCR, ThermoFisher Scientific), 0.3 µmol l<sup>-1</sup> of each forward and reverse primer, 10 nmol l<sup>-1</sup>/100 Nm ROX Solution, nucleases-free water to a final volume of 25 µl. The reaction was completed in AriaMx Real-Time PCR (Agilent Technologies, USA) using a two steps protocol: initial denaturation at 95 °C for 10 min, then 40 cycles of denaturation at 95 °C for 15 s followed by annealing/extension at 60 °C for 60 s. A melting curve protocol was run at the end of the PCR by heating at 95 °C for 30 s followed by a 65 °C for 30 s and 95 °C for 30 s. The expression levels of target genes were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative gene expression ratios (RQ) between treated and control groups were calculated using the formula:  $RQ = 2^{-\Delta\Delta Ct}$  (21).

**Table (1)** Primers used for SYBR green quantitative real-time PCR

Gene	Sequences (5'→3')	References	accession
<b>Notch1</b>	CCA GCA GAT GAT CTT CCC GTA C ACT GCC GCT ATT CTT GTC CC	(22)	XM_032903023.1
<b>DII-4</b>	TTC CAG GCAACC TTC TCC GA ACT GCC GCT ATT CTT GTC CC	(23)	XM_032903968.1
<b>Jagged-1</b>	CCT CGG GTC AGT TTG AGC TG CCT TGA GGC ACA CTT TGA AGT A	(24)	XM_032904296.1
<b>Hes1</b>	CCA GCC AGT GTC AAC ACG A AAT GCC GGG AGC TAT CTT TCT	(25)	XM_032900059.1
<b>Hey1</b>	GCG CGG ACG AGAATG GAAA TCA GGT GAT CCA CAG TCA TCT G	(25)	NM_010423.2
<b>VEGF</b>	GTACCTCCACCATGCCAAGT TCACATCTGCAAGTACGTTTCG	(26)	XM_032900655.1
<b>SDF-1</b>	GAG AGC CAC ATC GCC AGA G TTT CGG GTC AAT GCA CAC TTG	(27)	AF189724.1
<b>EPSCm</b>	GACCTGCCTTGGTGTCTGTGC AGCAACCACACCAGCTACAAT	(28)	XM_032888182.1
<b>GAPDH</b>	AGT TCA ACG GCA CAG TCA A TAC TCA GCA CCA GCA TCA CC	(29)	XM_032902285.1

**Western Blot**  
Anti-rabbit polyclonal antibodies against Notch 1 (abcam, ab8925), anti-rabbit

monoclonal antibodies against Jag1 (abcam, ab109536, [EPR4290]), anti-Rabbit monoclonal antibody against Hes1 (abcam, ab95439, [EPR4226]), and anti-rabbit polyclonal antibodies against GAPDH were used. Protein extraction was performed using ice-cold 1X cell lysis buffer containing 50 mmol Tris (SRL, Mumbai, India), 1 mmol EDTA (Fischer Scientific, New York), 150 mmol NaCl (Sigma Aldrich), 1 mol sodium fluoride (Fischer Scientific, Qualigens, Mumbai), 0.1% sodium dodecyl sulfate (SDS; Fischer Scientific), 1% Triton X-100 (Sigma Aldrich), 2 mmol phenylmethylsulfonyl fluoride (Sigma-Aldrich), and 4% protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Whole tissue specimens were minced and homogenized by passing through 20G, 22G, and 26G hypodermic needles.

The resultant cell lysates were agitated on ice for 30 minutes followed by centrifugation at 21,000g for 30 minutes to collect the supernatant. Protein concentration was estimated by the Folin-Lowry method using a spectrophotometer (Beckman Coulter Inc, Indianapolis, Indiana). The extracted protein was incubated in Laemmli buffer for 10 minutes at 95°C. Protein (50 mg loading) was resolved using 10% SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membrane (Amersham Biosciences, Bucks, United Kingdom). The blot was blocked with 5% nonfat dry milk (NFDM) in 1% TBS with Tween 20 overnight at 4°C. The membrane was incubated with anti-Notch 1, Jag1 and Hes1 and GAPDH antibodies (1:500; Ab3209, Millipore) at room temperature for 2 hours followed by incubation with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5000, Millipore) for 2 hours at room temperature.

Detection was performed with Super Signal West Femto substrate (Thermo Scientific, Waltham, Massachusetts) on photographic films (Eastman Kodak Co, Rochester, New York). The later blot was stripped using stripping buffer (62.5 mmol Tris, 2% DS, 100 mmol  $\beta$ -Mercaptoethanol) for 10 minutes at 60°C to detect housekeeping protein. GAPDH was used as housekeeping protein and detected using MAB1501 (Millipore) at a 1:5000 dilutions. After washing twice with 1X TBST, densitometric analysis of the immunoblots was performed using Image analysis software on the Chemi Doc MP imaging system (Version 3) produced by Bio-Rad (Hercules, CA).

## **Histological Analysis**

At the end of the experiment, the rats were anesthetized by sodium thiopental (40 mg/kg IP) after 12 h of fasting. Then, vascular perfusion fixation through the left ventricle was performed. The rats were fixed on an operating table to take skin specimens. The half of the skin tissue which collected from rats in all groups, was fixed in 10% buffered formol saline, embedded in paraffin, and sectioned at 4.0  $\mu$ m. The sections were dehydrated with successive concentrations of ethanol and washed twice in distilled water. The sections of the skin tissue at day 7 & 14 were stained with hematoxylin and eosin (H&E) and with Masson's trichrome in accordance with the protocols of the manufacturer to detect the reepithelialization/ granulation tissue formation and collagen deposition, respectively. Finally, the histological sections were observed and analyzed under a microscope (Leica DMR 3000; Leica Microsystem) by two blinded experienced investigators (30).

## **Immunohistochemical staining**

For detection of new vessel formation, the wound areas were analyzed using CD31 primary antibody (rabbit monoclonal primary antibody, SAB5500059, Sigma Aldrich, USA). For the detection of basal keratinocyte proliferation, the PCNA primary antibody was used (rabbit polyclonal Anti-Proliferating Cell Nuclear Antigen antibody, SAB2701819, Sigma-Aldrich, USA). For detection of adipose derived MSCs(ADSCs) in cutaneous tissues after injection in both treated groups group IV(DM+ADSCs) & group V (DM+ADSCs+PRP), the CD105 antibody (rabbit, polyclonal primary antibody, SAB1306487, Sigma Aldrich, USA) was used.

Briefly, after fixing, embedding in paraffin, and dewaxing, the tissue sections were blocked in 3 % normal goat serum/0.3 % Triton X-100/ 0.1 % BSA (Sigma Aldrich) in PBS. The sections were then incubated for 24 hours at 4 °C with the primary antibody (primary) against CD31 & PCNA respectively (1:100 dilution), followed by goat anti-mouse IgG (secondary) for each primary antibody for 1 hour at room temperature. After hematoxylin staining, tissue sections were washed and then dehydrated with ethanol, treated with dimethylbenzene, and sealed for microscopic analysis by two blinded experienced investigators (30).

### **Morphometric study**

The mean area percentage of collagen fiber deposition as indicated by Masson's trichrome staining, the mean area percentage of PCNA, the number of CD31 positive vessels were quantified to detect the neoangiogenesis and CD105 surface marker of ADSCs were measured in five images from five non overlapping fields from each rat of each group using the Image-Pro Plus program version 6.0 (Media Cybernetics Inc., Bethesda, Maryland, USA).

### **Statistical Analysis**

Statistical analysis was performed using the statistical software package SPSS for Windows (Version 16.0; SPSS Inc., Chicago, IL, USA). GraphPad Prism 8.0.2 (GraphPad Software, San Diego, CA, USA) was used for graphical representation. Differences between groups were evaluated using one-way Analysis of Variance (ANOVA) followed by Tukey test, and Kruskal Wallis followed by Mann-Whitney U test regarding parametric and non-parametric data, respectively. Data are expressed as mean  $\pm$  standard error (SEM) (parametric) and median (non-parametric), P-value <0.05 was considered significant.

## **Results**

### **Confirmation of adipose derived MSC isolation**

ADSCs were initially identified after 2 weeks' isolation in culture by an inverted microscope as spindle-shaped cells between rounded cells (Figure 2a) and injected ADSCs labeled with GFP were observed using a fluorescent microscope (Figure 2b). Moreover, CD105 immunoexpression was investigated in cutaneous tissue 2 weeks' post-transplantation as it is type I membrane glycoprotein receptor which increased upon culture passages of MSCs (Figure 2c). Cell surface marker expression confirmed ADSCs identity via CD90 (90.38% positive expression), CD 105 (99.82% positive), and CD45 (0.2%) being consistent with ISCT MSC guidelines (31) (Figure 2c). Confirmation of adipogenic, osteogenic and chondrogenic differentiation was also established (Figures 2d, e & f). Supporting evidence for homing of ADSCs in cutaneous tissue, the immune expression of CD105 (surface marker of ADSCs) were detected in treated groups; group IV(DM+ADSCs) & group V(DM+ADSCs+PRP), with better immune-expression in group V indicating better homing with combined therapy of PRP with ADSCs (Figure 2g, h& i).

### **Enhanced wound closure rate in ADSCS+PRP group via modulating Notch signaling pathway**

The mean wound closure rate at days 3, 7, 10, and 14 post wound infliction were  $21.5 \pm 2.0$ ,  $57.2 \pm 1.3$ ,  $71.5 \pm 0.9$ , and  $90.9 \pm 1.1\%$  respectively in the sham group (group II) while, in the diabetic group (group III), the wound closure rates were significantly decreased ( $4.7 \pm 0.6$ ,  $0.9 \pm 0.5$ ,  $20.3 \pm 0.8$ , and  $50.5 \pm 1.5\%$  on days 3, 7, 10, and 14, respectively), with significant increased wound area (1.1, 1.4, 1.6 and 2.6 respectively) compared to sham group, reflecting lower wound closure rates compared to sham group. In the treated groups, the wound closure rate was ( $9.0 \pm 1.3$ ,  $39.8 \pm 1.0$ ,  $61.0 \pm 1.2$ , and  $75.3 \pm 1.2\%$ ) in PRP group (group IV), ( $15.1 \pm 1.6$ ,  $48.9 \pm 1.6$ ,  $68.4 \pm 1.5$ , and  $81.4 \pm 1.2\%$ ) in ADSCs group (group V), and ( $21.5 \pm 1.3$ ,  $59.2 \pm 1.4$ ,  $80.2 \pm 0.8$ , and  $91.4 \pm 0.9\%$ ) in PRP+ADSCs group (group VI) at days 3, 7, 10, and 14 days respectively. The PRP+ADSCs group showed significant decreased wound area by 12.3% and 6.2% at days 10 and 14, respectively when compared to diabetic group (Figure 3).

## **Histological findings underlying the accelerated diabetic wound healing treated with ADSCs combined with PRP via modulating Notch signaling pathway**

### **H&E results**

Examination of H&E stained sections of the Control group (group I) demonstrated the normal histological layers and structure of thin skin. The epidermis was composed of a keratinized stratified squamous epithelium, consisting predominantly of keratinocytes arranged in four strata. The stratum basale was formed of a single layer of cuboidal to low columnar cells with large basal oval vesicular nuclei. The stratum spinosum consisted of polyhedral cells with rounded vesicular nuclei, while the stratum granulosum cells appeared flattened with numerous intensely basophilic keratohyalin granules. Finally, the stratum corneum was the most superficial, non-cellular, homogenous acidophilic layer. Immediately beneath the epidermis, the dermis was seen formed of two layers. The superficial papillary layer contained thin interlacing collagen fibers, connective tissue cells, and numerous blood capillaries. The deeper reticular layer was thicker than the papillary layer, and poorly demarcated from it. It was less cellular and formed of thicker collagen bundles running in different directions (Figure 4a).

Examination of H&E stained sections taken 7 days post wound infliction in the sham group (group IIa) revealed healed wounds with an intact epidermis and dermis. The epidermis appeared thinner than that of the control group and was arranged in three layers. The papillary layer of the dermis was thin with minimal collagen deposition and inflammatory cell infiltration. Collagen bundles in the reticular layer were thicker than that of the control group arranged parallel to the surface (Figure 4b). Sections examined 14 days post wound infliction in sham group (group IIb) showed similar epidermal thickness and structure to that of the control group. The papillary layer of the dermis showed abundant fine interlacing collagen fibers, fibroblasts with spindle shaped nuclei, and numerous blood capillaries, with a notable absence of inflammatory infiltration. The reticular layer revealed collagen bundles thicker than those of the control group (Figure 4c).

The diabetic group (group III) showed delayed wound healing and prominent histological alterations. Sections of the 7<sup>th</sup> day (group IIIa) showed interrupted epidermis with wound beds covered by a single

layer of squamous cells. The epidermis on either side of the wound beds appeared thin with disorganized keratinocytes and notable absence of keratin. Both layers of the dermis showed massive inflammatory infiltration with minimal collagen deposition (Figure 4d). At the 14<sup>th</sup> day (group IIIb), the thin diabetic skin revealed persistent interruption of the epidermis. The wound bed contained pyknotic nuclei and the epidermis on either side of the wound appeared disorganized with pyknotic nuclei and a persistent absence of keratin. The papillary layer showed areas of deficient collagen deposition and absence of blood capillaries, while the reticular layer showed thick collagen bundles, and less dense collagen fibers. Both layers showed persistent inflammatory infiltration (Figure 4e).

Treatment of wounds with PRP (group IV) and ADSCs (group V) both individually and in combination (group VI) lead to acceleration of wound healing when compared to the sham and DM groups at both the 7<sup>th</sup> and 14<sup>th</sup> days post wound infliction.

Examination of the PRP treated group at the 7<sup>th</sup> day (group IVa) showed healed wounds with intact dermis and epidermis. The epidermis appeared thin with few keratohyalin granules and absence of keratin. The papillary layer showed areas of fine collagen fiber deposition with inflammatory infiltration and few blood capillaries. The reticular layer showed thick collagen bundles (Figure 4f). At the 14<sup>th</sup> day (group IVb), the epidermis appeared thicker with prominent keratohyalin granules and keratin. Collagen of the dermis was arranged in thick bundles parallel to the surface (Figure 4g). Sections from the ADSCs treated group at the 7<sup>th</sup> day (group Va) showed intact thin skin. The epidermis appeared thin with few keratohyalin granules and keratin. The papillary layer showed interlacing collagen fibers, blood capillaries, and absence of inflammatory cells, while the reticular layer showed thin collagen bundles running parallel to the surface (Figure 4h). At the 14<sup>th</sup> day (group Vb), the epidermis appeared thicker, with more prominent keratohyalin granules and keratin. The papillary layer showed more collagen fibers and blood capillaries, while the reticular layer had thick collagen bundles (Figure 4i).

PRP+ADSCs treated group at the 7<sup>th</sup> day (group VIa) revealed intact thin skin. The epidermis showed all keratinocyte layers. Fine collagen fibers and blood capillaries in the papillary layer, and thick collagen bundles in the reticular layer (Figure 4j). At the 14<sup>th</sup> day (group VIb), the epidermis appeared thicker. Abundant, fine, interlacing collagen fibers and numerous blood capillaries were seen in the papillary layer and reticular layers showed thick collagen bundles and numerous hair follicles (Figure 4k).

### **Masson's trichrome results**

In the control group (group I), dermal collagen was seen as fine interlacing fibers in the papillary layer, and thick, irregular blue bundles in the reticular layer (Figure 5a). The sham group at the 7<sup>th</sup> day (group IIa) showed fine collagen fibers in the papillary layer and thick collagen bundles parallel to the surface in the reticular layer (Figure 5b). At the 14<sup>th</sup> day (group IIb), abundant fine interlacing collagen fibers were seen in the papillary layer and thick collagen bundles in the reticular layer (Figure 5c). The diabetic group (group III) revealed an evident decrease in collagen in both the papillary and reticular layers. At the 7<sup>th</sup> & 14<sup>th</sup> day (group IIIa & IIIb), both layers showed pale fine collagen fibers with some areas deficient collagen

deposition. Few areas showed thick collagen bundles at 14<sup>th</sup> day (Figure 5d &5e). On the other hand, the treated groups (group IV, V&VI) showed a progressive increase in fine collagen fiber deposition in the papillary layer with improvement in the organization of the thick collagen bundles which ran parallel to the surface in the reticular layer. The best collagen deposition and organization was observed in group VI compared to the control group (Figure 5f- 5k).

### **Immunohistochemistry staining results**

Immunohistochemical staining with anti-PCNA antibody was performed to assess cellular proliferation of the epidermis in the wound area. In group I, the basal layer of keratinocytes showed intense reaction in many cells (Figure 6a), while in group II, there was moderate reaction on 7<sup>th</sup> day (Figure 6b) and the reaction became intense on the 14<sup>th</sup> day in the basal layer of keratinocytes, comparable to that of the control group (Figure 6c). On the other hand, in group III, a weak reaction was observed in basal layer of keratinocytes at the 7<sup>th</sup> and 14<sup>th</sup> day (Figure 6d & 6e). In the treated groups (group IV, V &VI), the intensity of reaction in basal layer of keratinocytes increased from moderate to intense reaching a reaction comparable to the control at the 14<sup>th</sup> day of group VI (figure 6f-k).

Immunohistochemical detection of angiogenesis (new capillary formation) was performed using endothelial CD31 marker. In the control group (group I), a moderate CD31 expression was observed in the capillaries of the papillary layer of the dermis (Figure 7a). In the sham group (group II) CD31 expression was observed at the 7<sup>th</sup> day which peaked at the 14<sup>th</sup> day, (Figure 7b &7c). In the diabetic group (group III), a negative CD31 reaction was observed on both days (Figure 7d, e). On the other hand, the treated groups (groups IV, V, and VI) showed new vessel formation with CD31 immuno-expression at the 7<sup>th</sup> day, and peaked at the 14<sup>th</sup> day (Figure 6f-6k).

### **Morphometric study**

In H&E stained sections, the mean epithelial thickness was  $236.4 \pm 1.1 \mu\text{m}$  in the control group (group I), while in the sham group (group II) it was  $219.8 \pm 1.0 \mu\text{m}$  on the 7<sup>th</sup> day and  $233.7 \pm 1.4 \mu\text{m}$  on the 14<sup>th</sup> day. In the diabetic group (group III), the significant decreased epithelial thickness was observed at both days ( $0.0 \pm 0.0 \mu\text{m}$  and  $18.4 \pm 1.9 \mu\text{m}$  on days 7 and 14) respectively when compared to the sham group, the ( $p < 0.05$ ). Furthermore, a significant increased epithelial thickness was observed in all treated groups (group IV, V &V) with the most significant increase observed in group VI when compared to diabetic group. The mean epithelial thickness of the treated groups was ( $184.7 \pm 5.1$ ,  $222.1 \pm 2.4$  and  $231.4 \pm 2.4 \mu\text{m}$  respectively) on the 7<sup>th</sup> day and ( $197.1 \pm 12.8$ ,  $227.4 \pm 1.7$  and  $237.6 \pm 1.2 \mu\text{m}$  respectively) on the 14<sup>th</sup> day, ( $p < 0.05$ ) (Figure 4l).

In Masson trichrome stained sections, the mean area percentage of dermal collagen was ( $23.2 \pm 1.0 \%$ ) in the control group (group I). In the sham group (group II), it was ( $19.6 \pm 0.4 \%$ ) on the 7<sup>th</sup> day and ( $22.3 \pm 0.9 \%$ ) on the 14<sup>th</sup> day. In the diabetic group (group III), the significant decreased collagen deposition was observed ( $17.4 \pm 0.2 \%$ ) on the 7<sup>th</sup> ( $17.1 \pm 0.3 \%$ ) and 14<sup>th</sup> days when compared to the sham group

( $p < 0.05$ ). Following treatment with PRP and ADSCs, there was significant increased collagen deposition in treated groups (IV, V & IV) with the most significant increase observed in group VI. The mean area percent of collagen deposition of the treated groups at 7<sup>th</sup> day were ( $18.4 \pm 0.3$ ,  $19.2 \pm 0.2$  &  $20.8 \pm 0.5$  % respectively) ( $p < 0.05$ ), while the mean area percent of collagen deposition at 14<sup>th</sup> day were ( $18.5 \pm 0.2$ ,  $19.8 \pm 0.5$  and  $22.5 \pm 0.5$  respectively) ( $P < 0.05$ ) (Figure 5I).

In PCNA stained sections, the mean area percentage of PCNA was ( $1.3 \pm 0.0$  %) in the control group (group I). In the sham group (group II), it was ( $0.4 \pm 0.0$  %) on the 7<sup>th</sup> day and ( $1.3 \pm 0.0$  %) on the 14<sup>th</sup> day. In the diabetic group (group III), the significant decreased mean area percentage of PCNA was observed ( $0.1 \pm 0.0$  %) on both the 7<sup>th</sup> day and 14<sup>th</sup> days when compared to group II with ( $p < 0.05$ ). Following the treatment with PRP and ADSCs, there was significant increased mean area percentage of PCNA in treated groups (IV, V & IV) with the most significant increase observed in group VI. The mean area percent of PCNA at 7<sup>th</sup> day were ( $0.6 \pm 0.0$ ,  $1.0 \pm 0.0$  &  $1.3 \pm 0.0$  %) respectively ( $p < 0.05$ ), while the mean area percent of PCNA at 14<sup>th</sup> day were ( $0.8 \pm 0.1$ ,  $1.0 \pm 0.0$  &  $1.3 \pm 0.0$ ) respectively ( $p < 0.05$ ) (Figure 6I).

Morphometric analysis of CD 31 expression showed a CD 31 positive capillary count of ( $3.4 \pm 0.2$ ) in the control group (group I). The granulation tissue of the wound of the sham group (group II) had a count of ( $2.7 \pm 0.3$ ) at the 7<sup>th</sup> day and ( $3.6 \pm 0.2$ ) at the 14<sup>th</sup> day. In diabetic group, there was significant decreased in capillary count on both days ( $0.0 \pm 0.0$ ) when compared with sham group ( $p < 0.05$ ). Following treatment with PRP and ADSCs, there was a significant increase in CD 31 positive capillary count in the treated groups (IV, V & IV) with the most significant increase observed in group VI. The capillary count at the 7<sup>th</sup> day was ( $1.9 \pm 0.3$ ,  $2.4 \pm 0.3$  &  $5.0 \pm 0.7$ ) respectively ( $p < 0.05$ ), while at 14<sup>th</sup> day was ( $2.0 \pm 0.3$ ,  $3.3 \pm 0.3$  &  $5.9 \pm 0.8$ ) respectively ( $p < 0.05$ ) (Figure 7I).

### **Effect of PRP and/or ADMSCs on gene expression of Notch1 pathway and angiogenic key elements in rat diabetic wound**

To elucidate the role of Notch signaling pathway relevant to diabetic wound healing, the expression of Notch receptor (Notch1), two Notch ligands (Dll4 & Jag1) and two Notch target genes (Hes1 & Hey1) were detected. qPCR was used to assess the expression of Notch1 pathway-related genes in the diabetic wound.

As shown in **Figure 8**, Sham group (group II) at day 7 showed significant upregulation of Notch1 and its downstream genes including Notch1, Dll4, Jag1, Hes1 and Hey1 when compared to control group (group I) ( $p < 0.01$ ). Nevertheless, Group II at day 14 showed non-significant upregulation of Notch1 and its downstream genes when compared to group I. In contrast, Notch1 and its downstream genes showed significant higher expression levels in diabetic group (group III) than those in group I ( $p < 0.01$ ). The expression of Notch1 and its downstream genes, in all treated groups (IV, V and VI), was found to be significantly decreased compared to group III. Group VI at day 14 showed no significant changes in the expression of Notch1 pathway-related genes when compared to either group I or group II. On the other

hand, group VI showed significant changes compared to group IV and group V both at day 7 and day 14 ( $p < 0.01$ ).

Angiogenic gene (VEGF), epidermal stem cell-related genes (EPSCm and SDF-1) were significantly upregulated in Sham group (group II) compared with those in control group (group I) ( $p < 0.05$  for VEGF and SDF-1 and  $p < 0.01$  for EPSCm at day 7,  $p < 0.05$  for the three genes at day 14). Diabetic group (group III) displayed significant downregulation of these genes compared to either group I or II ( $p < 0.01$ ). Nevertheless, these genes were unchanged between group III and group IV. Further, both group V and VI displayed significant up-regulation of these genes when compared to group III ( $P < 0.01$ ). Moreover, group VI showed significant changes compared to group IV and group V both at day 7 and day 14.

### **Effect of PRP and/or ADMSCs on protein levels of Notch1 pathway key elements in rat diabetic wound**

Western blot results of Notch1, Jag1 and Hes1 showed a similar trend to that of the gene expression analysis and confirmed it.

As shown in **Figure 9**, Sham group (group II) at day 7 showed significant upregulation of protein levels of Notch1 ( $p < 0.05$ ), Hes1 ( $p < 0.01$ ) and Jag 1 ( $p < 0.05$ ) when compared to group I. However, at day 14 group II showed non-significant upregulation of the aforementioned proteins when compared to control group (group I).

Further, Notch1, Hes1 and Jag 1 showed significant higher expression levels in group III than those in group I ( $p < 0.05$ ). The expression of Notch1 in all treated groups (IV, V and VI) was found to be significantly decreased compared to group III ( $p < 0.05$ ). The expression of Hes 1, and Jag1 showed non-significant decrease in group IV and V and significant decrease in group VI at day 7, and significant decrease in all treated groups at day 14 when compared to group III. Group VI at day 14 showed no significant changes in the expression of Notch1 pathway-related genes when compared to either group I or group II ( $p < 0.05$ ).

## **Discussion**

Wound healing is definitely a complex process coordinated by numerous molecular events leading to closure of the wound with or without scar formation. Typically, the events that occur soon after a skin injury could be allocated into four overlapping phases: coagulation and hemostasis, inflammation, proliferation and remodeling. The proper and coordinated progress of such processes is essential to a normal and effective wound healing. Insufficient wound healing take place when one or more underlying molecular processes within the different phases are usually disrupted (32). Therefore, wound healing is a natural response, but in severe or chronic conditions, such as burns and diabetes, this process is insufficient to achieve effective repair.

Epidermal stem cells (EPSCs) are a multipotent cell type and are committed to the formation and differentiation of the functional epidermis (33). The microenvironment of stem cells, called "stem cell

niches,” performs a key role in regulating the stem cells proliferation, migration and differentiation throughout a network system of numerous interconnected signaling pathways. Among these pathways, the Notch signaling pathway which is essential constituents of stem cell “niches” which play a vital role in skin development and wound repair. After skin injury, cytokines concentration as well as the extracellular matrix (ECM) components are changed resulting in stem cell niche affection and Notch signaling pathway activation. Hence, the proliferation and differentiation of wound EPSCs are prompted, ultimately contributing to wound healing or scar formation (34).

The sham operated group of the current study proved that the activation of Notch1 pathway resulted in improved wound closure as evidenced by improved epidermis layer thickness, rejuvenated skin appendages along with more organized and regular collagen fibers arrangement leading to intact epidermis and dermis, which were more or less normal in structure. Moreover, the EPSCs marker ( $\beta$  Integrin), Notch1 and its ligands DLL4 & Jag1, with its downstream target genes Hes1 & Hey1 were significantly increased. Hes1 & Hey1 are considered as chief target genes in the Notch1 signaling pathway, and they play a vital role in maintaining the proliferation potential of EPSCs confirming that the Notch1 signaling plays a significant role in retaining the homeostasis of epidermal epithelial cells. This was confirmed by the significant increased immune-expression of PCNA in the basal layer of the epidermis compared to the normal skin, which indicated an increased EPSC proliferation. Concomitant with these results, Yang et al., 2016 (35) reported that initial activation of Notch1 signaling throughout wound healing could support EPSC proliferation and preserve their low differentiation potential and even multi-directional differentiation potential. Furthermore, Yang et al 2016 (35) & Zhou et al., 2018 (36) stated that, Notch1 is extensively expressed on EPSCs which were traced mainly in the basal layer of the epidermis, so, if the Notch signaling pathway was blocked, EPSCs proliferation would be inhibited hindering the epithelialization process leading to loss of skin barrier function.

Moreover, sham operated group showed a significant increased Jag 1 expression, which is the first ligand of Notch receptor expressed in all skin layers. It plays a significant role in controlling the differentiation of EPSCs (37). Concomitant with these results, Chigurupati 2007 (38), verified that mice treated with the Notch ligand, Jagged, showed accelerated wound closure (as assessed by surface wound size) suggesting that these effects were mediated by the Notch pathway, so, Jag1 mediated the “dialogue” of Notch signaling in cutaneous tissue, controlling EPSC proliferation and differentiation as well as playing a role in wound healing and scar formation. This explains that, the Notch signaling pathway could affect the biological microenvironment (“niche”) of EPSCs. This could be attributed to the role of Notch signaling pathway in the angiogenic process. Indeed, vascular endothelial cells express receptors Notch1, 4 and ligands Delta-like 1, 4 in addition to Jag1. Thus, Notch1 and Dll4 play vital role in angiogenic budding. The budding is directed by endothelial tip cells which express high amounts of Dll4. For this purpose, Dll4 is placed at the protruding front directed towards to angiogenic signals (39). Such outcomes were supported by the results of the current study, as evidenced by the improved vascularity in the wound healing process of sham operated group, which is confirmed by the significant increase in CD31 immuno-expression indicating new blood vessels formation & by the significant increase in VEGF & STDF-1 gene expression. These results were explained by Chigurupati et al 2007 (38), who reported that

Notch signaling affected several behaviors of vascular endothelial cells which are critical for angiogenesis. Angiogenesis includes endothelial cell migration into the surrounding tissue, cell proliferation, alignment and tube formation, recruitment of parenchymal cells and a return to quiescence. So, activation of Notch in wound healing process enhanced vascular endothelial cell proliferation, migration and tube formation (40).

Regarding the inflammatory phase of the wound healing, the inflammatory cell infiltration of sham operated group in the current study was increased during the first week of wound healing confirmed by histological study then decreased after that in the proliferation phase of the wound healing. Consistent with these findings, Kimbal et al. 2017 (41) stated that Notch is critical for the early inflammatory phase of wound healing and directs the production of macrophage-dependent inflammatory mediators. These results demonstrated that Notch signaling is important in directing macrophage function in wound repair and provided a translational target for the treatment of non-healing diabetic wounds.

In the diabetic group of the current study, there was delayed wound healing evidenced by a significant increase in wound's mean surface area, significant decrease in epidermal thickness and impaired angiogenesis as compared with the control groups. These results were accompanied by highly significant increase in gene expression of Notch-1 signaling pathway, as there was pathological over-activation of notch1 & its downstream genes, combined with significant decrease in gene expression of VEGF, SDF-1 and EPSCm ( $\beta$  Integrin). These results were further confirmed by significant decreased CD31 immune-expression indicating defective new blood vessels formation & by significant decrease in PCNA immune-expression indicating decreased EPSCs proliferation. So, these results suggested a crucial role of pathological upregulation of Notch signaling in both diabetic EPSCs & diabetic endothelial progenitor cells dysfunction.

Many researchers demonstrated pathological activation of Notch 1 signaling in various cells essential for wound healing under diabetic condition like EPSCs, keratinocytes, dermal fibroblasts and dermal microvascular endothelial cells. When these cells were exposed to high glucose level, the Notch1 signaling increased as reflected by increased expression levels of its target Hey1. In addition, pathological activation of Notch1 by high glucose levels resulted in negative effects on the migration of keratinocytes and fibroblasts as well as on the tube formation of vascular endothelial cells, all these processes are considered crucial for wound healing (8), (42).

Miloudi et al 2019 (43) reported that chronic hyperglycemia-induced Notch 1 over-activation aggravated the rapid destabilization of the vascular endothelial cells leading to phosphorylation of VEGFR2 with increased production of NO. This in turn resulted in dissociation of vascular endothelial cadherin/ $\beta$ -catenin complex. So, the high levels of reactive oxygen species induced an endothelial progenitor cells (EPCs) deficit leading to impairment of their abilities of angiogenesis, proliferation, differentiation, migration, and adhesion.

The expression of SDF-1, a vital factor for recruitment of EPCs is negatively controlled by Notch signaling. This provides a mechanism for how angiogenesis is regulated via Notch signaling. In diabetic

wound healing, pathologically activated Notch pathway impairs EPCs incorporation into the wound site secondary to decreased SDF-1 expression. This leads to a significant defect that contributes to impaired wound healing in diabetes Caiado et al 2007 (44). In addition, chronic hyperglycemia leads to upregulation of Dll4, activating both canonical and rapid non-canonical Notch1 pathways. Subsequently, a hyperglycemia-induced Dll4– Notch1 positive feedback loop has been recognized to contribute to pathogenic sustained Notch activation in diabetes (45). This is in concordance with the negative impact of Dll4- dependent Notch1 signaling on angiogenesis (8).

Therefore, Notch inhibition in diabetic wounds lead to improvement in EPSCs proliferation as well angiogenesis via facilitating the recruitment of EPCs. These results reflected the profound consequences of an increased Notch signaling for diabetic wounds (46). Subsequently, Notch1 signaling blockage both *in vitro* as well as *in vivo* through either genetic or pharmacological methods was found to enhance wound healing in diabetes, via numerous mechanisms central for wound healing as cellular proliferation, migration, and angiogenesis. This signifies that Notch1 signaling is a new potential therapeutic target for diabetic wound (47), (48), (49).

Interestingly, recent studies have demonstrated that cell therapy and growth factors enhance diabetic wound healing. These researches suggested that MSCs have the ability to differentiate into other different cell types within the injured tissue to stimulate repair and regeneration of skin. Also, PRP may provide a suitable microenvironment for MSCs to enhance proliferation and differentiation (9). Therefore, in the current study, diabetic wounds were treated with adipose derived MSCs (ADSCs) and PRP both individually and in combination to compare their therapeutic efficacy in diabetic wound healing and to assess their relation to Notch signaling pathway.

The current study revealed that Notch1 pathway-related genes were significantly downregulated to near the normal levels in ADSCs plus PRP group compared to the other treated groups and the diabetic group. There was improved wound healing with decline in wound's mean surface area besides the increase in all other parameters (area percentage of collagen, epidermal thickness, and CD 31 positive capillaries) in all treated groups, in comparison to the diabetic groups with significant amelioration detected in the ADSCs plus PRP group. Furthermore, the EPSCs were increased in all treated groups confirmed by gene expression of EPSC marker ( $\beta$  Integrin) and PCNA immune-expression in the epidermal layer with significant improvement being observed in the ADSCs plus PRP in comparison to all treated groups and the diabetic group. Concomitant with these results, Motegi and Ishikawa 2017(50) revealed that intradermal or intravenous administration of MSCs enriched cutaneous wound healing of acute and chronic skin injuries, for example diabetic ulcers, acute excisional and incisional wounds, radiation ulcers as well as burns in animals and humans. In animal models, the exogenous application of MSCs by topical and/or subcutaneous injection into incisional full-thickness wounds in normal or diabetic animals revealed speeding up of wound healing associated with increased reepithelization, angiogenesis and decreased inflammation in the wounds (51). Sorrell and Caplan 2010 (52) suggested two core mechanisms of wound healing acceleration by MSCs: (I) paracrine communication with resident cells in the wounds, infiltrating inflammatory cells, and antigen-presenting cells through the release of cytokines,

growth factors, and ECM; and (II) their differentiation into resident EPSCs. These functions of MSCs can enhance reepithelization, angiogenesis, granulation tissue formation, ECM remodeling and inhibit inflammation in the wounds.

In addition, results of the current study regarding angiogenesis clearly suggest that the ADSC and PRP therapy could induce a strong angiogenic effect in wound healing as CD31 immuno-expression as well as the gene expression of VEGF & SDF-1 were significantly increased in all treated groups with better results in ADSCs plus PRP group in comparison with diabetic wound group. This angiogenic response is critical for wound healing as it is necessary to increase oxygen and nutrient supply and to ensure the survival of keratinocytes. Moreover, it helps in sustaining the newly formed granulation tissue composed of a large number of blood vessels, which were typically functioning and contained red blood corpuscles. The SDF-1 secreted from MSCs induces the survival of vascular endothelial cells, promotes vascular branching, and pericytes recruitment. These paracrine effects of MSCs play essential roles in angiogenesis rather than their direct differentiation to endothelial cells and/or pericytes (51). In addition, some studies have revealed that angiogenic factors like VEGF, angiopoietins and hepatic growth factor, which are released from injured tissue assist the recruitment of MSCs to the wound site (53). In line with these results, Li et al 2006 (54) stated that, MSCs might differentiate into mature endothelial cells resulting in new blood vessels formation as well as expression of angiogenic growth factors through paracrine matter stimulating the neovascularization at the site of the wound. These results were explained by Volarevic et al 2010, who stated that MSCs administration lead to secretion of some growth factors as well as some cytokines, such as PDGF, VEGF, bFGF and angiopoietin-1 leading to enhancement of angiogenesis and wound healing (55). Moreover, Suh et al. (56) reported that in a mouse model, MSCs-treated groups demonstrated an enhanced wound-closure rate due to recruitment of monocytes/macrophages in addition improving the neovascularization. Recently, it has been found stated that MSCs transplantation could activate EPCs leading to wound healing acceleration in a diabetic wound model (57).

Xie et al.2013 (58) suggested that Notch signaling controlled MSCs homing to the injured tissues as via SDF-1a/CXCR4 axis. CXCR4, the specific chemokine receptor of SDF-1a, is expressed in early passage MSCs and plays pivotal role in the process of MSCs homing. Interestingly, Williams et al (59) found that in endothelial cells, Notch signal activation induced by Dll4 down-regulates CXCR4 expression therefore inhibits responses toward SDF-1. This is the first report linking the Notch signaling pathway to CXCR4 regulation. Blocking Notch signaling may enhance MSCs migration partly by up regulating the CXCR4 expression in MSCs. However, a significant barrier to the effective implementation of MSC therapy is the efficient engraftment of these cells into the injured tissues through interfering with Notch-CXCR4 signaling, which should significantly reduce the number of cells required to achieve therapeutic effects, and presumably provide better outcomes for patients. Moreover, Notch signaling plays an important role in MSCs differentiation. It had been shown that the Notch signaling pathway controls the mesenchymal progenitor cell proliferation and differentiation throughout skeletal development (60). Besides, Notch signaling preserves bone marrow mesenchymal progenitors via suppressing the osteoblast differentiation in bone marrow (61). In this context, Vujovic et al (62) examined the crucial role of Notch signaling pathway in human MSC proliferation and differentiation through using c-secretase inhibitors.

They found that inhibiting c-secretase decreased the proliferation of human MSC but it did not modify the expression of the osteoblast markers. This information suggested the essential role of Notch signaling pathway in regulation of MSCs proliferation.

However, cell therapy alone can result in up to 20% of wounds remaining unhealed (63). Researchers believe that this decreased efficacy may be due to the deficiency of numerous cytokines that encourage the migration and survival of EPSCs & EPCs. Additionally, owing to the inflammatory environment and the abnormal levels of growth factors in the wound area, the function of injected exogenous MSCs would be impaired due to the lack of stimulation by growth factors. The data of the current study coincides with these findings, supporting the hypothesis that MSCs in combination with PRP have a direct or indirect modifying effect on the angiogenesis via the growth factors as the PRP is a rich source of growth factors that stimulates angiogenesis in diabetic wounds improving the microenvironment for MSCs to work besides improving the niche of EPSCs. However, EPSCs and EPCs are insufficient alone for treatment of diabetic wounds as Li et al. reported that EPCs, which can repair damaged blood vessels and have angiogenetic abilities, are possibly suppressed due to the pathological activation of the Notch signaling pathway by chronic hyperglycaemia (64).

In conclusion, the present study demonstrated the potential usefulness of combined ADMSCs and PRP in diabetic wounds. This could be attributed to modulating pathologically up-regulated Notch 1 signaling, enhancing angiogenesis and triggering epidermal cells proliferation and recruitment.

## List Of Abbreviations

ADSCs: adipose derived mesenchymal stem cells

DLL4: Delta like canonical Notch ligand 4

DFU: diabetic foot ulceration

DM: diabetes mellitus

EPSCs: epidermal stem cells

Hes1: Hairy Enhancer of Split-1

Jag-1: Jagged-1

MSC: mesenchymal stem cell

PRP: Platelet-rich plasma

SDF-1: stromal cell-derived factor 1

VEGF: Vascular endothelial growth factor

# Declarations

## Acknowledgments

We would like to represent our acknowledgments for the research team of the Central Lab at Faculty of Medicine, Benha University.

**Funding** This research was partially funded from Benha University.

**Disclosure of conflict of interest:** None.

## Authors' contributions

NE, AAD, MMY, OM, BAS, AH, AN and RFS designed and planned the study. NE, RFS, MMA, MMY, AAD, AN, AAS, OM, DS, and DS performed the experiments. NE, RFS, AAD, EAME, BAS, MMA, ME, SF, EAE and YS collected the data, and RFS, MMY, NEM and ASF analyzed the data. NE, RFS, EAE, YS, AH, ADAD and NEM was a major contributor in writing the manuscript. NE amended the manuscript. All authors read and approved the final version of the manuscript.

## Ethics approval and consent to participate

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH publication No. 85–23, revised 1996). All protocols were approved by the institutional review board for animal experiments of the Faculty of Medicine, Benha University, Egypt.

**Data availability:** Data are available on reasonable request from the corresponding author.

## Consent for publication

Not applicable

## Competing interests

The authors declare that they have no competing interests.

# References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019 Nov;157:107843.
2. Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. *Ther Adv Endocrinol Metab.* 2018 Jan;9(1):29–31.

3. Morgun EI, Vorotelyak EA. Epidermal Stem Cells in Hair Follicle Cycling and Skin Regeneration: A View From the Perspective of Inflammation. *Front Cell Dev Biol.* 2020;8:581697.
4. Wang Z-L, He R-Z, Tu B, He J-S, Cao X, Xia H-S, et al. Drilling Combined with Adipose-derived Stem Cells and Bone Morphogenetic Protein-2 to Treat Femoral Head Epiphyseal Necrosis in Juvenile Rabbits. *Curr Med Sci.* 2018 Apr;38(2):277–88.
5. Hsu Y-C, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. *Nat Med.* 2014 Aug;20(8):847–56.
6. Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and Disease. *Physiol Rev.* 2017 Oct 1;97(4):1235–94.
7. Radtke F, Fasnacht N, MacDonald HR. Notch Signaling in the Immune System. *Immunity.* 2010 Jan;32(1):14–27.
8. Zheng X, Narayanan S, Sunkari VG, Eliasson S, Botusan IR, Grünler J, et al. Triggering of a Dll4-Notch1 loop impairs wound healing in diabetes. *Proc Natl Acad Sci U S A.* 2019 Apr 2;116(14):6985–94.
9. Hersant B, Sid-Ahmed M, Braud L, Jourdan M, Baba-Amer Y, Meningaud J-P, et al. Platelet-Rich Plasma Improves the Wound Healing Potential of Mesenchymal Stem Cells through Paracrine and Metabolism Alterations. *Stem Cells Int.* 2019;2019:1234263.
10. Chicharro-Alcántara D, Rubio-Zaragoza M, Damiá-Giménez E, Carrillo-Poveda JM, Cuervo-Serrato B, Peláez-Gorrea P, et al. Platelet Rich Plasma: New Insights for Cutaneous Wound Healing Management. *J Funct Biomater.* 2018 Jan 18;9(1).
11. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, et al. Human bone marrow and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. *Stem Cell Res Ther.* 2015 Jul 1;6:127.
12. Ebrahim N, Mandour YMH, Farid AS, Nafie E, Mohamed AZ, Safwat M, et al. Adipose Tissue-Derived Mesenchymal Stem Cell Modulates the Immune Response of Allergic Rhinitis in a Rat Model. *Int J Mol Sci.* 2019 Feb 18;20(4).
13. Pédelacq J-D, Cabantous S, Tran T, Terwilliger TC, Waldo GS. Engineering and characterization of a superfolder green fluorescent protein. *Nat Biotechnol.* 2006 Jan;24(1):79–88.
14. Sabry D, Noh O, Samir M. Comparative Evaluation for Potential Differentiation of Endothelial Progenitor Cells and Mesenchymal Stem Cells into Endothelial-Like Cells. *Int J Stem Cells.* 2016 May 30;9(1):44–52.
15. Kay AG, Dale TP, Akram KM, Mohan P, Hampson K, Maffulli N, et al. BMP2 repression and optimized culture conditions promote human bone marrow-derived mesenchymal stem cell isolation. *Regen Med.* 2015;10(2):109–25.
16. Yin W, Qi X, Zhang Y, Sheng J, Xu Z, Tao S, et al. Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. *J Transl Med.* 2016 Mar 15;14:73.

17. Ebrahim N, Ahmed IA, Hussien NI, Dessouky AA, Farid AS, Elshazly AM, et al. Mesenchymal Stem Cell-Derived Exosomes Ameliorated Diabetic Nephropathy by Autophagy Induction through the mTOR Signaling Pathway. *Cells*. 2018 Nov 22;7(12).
18. Galiano RD, Michaels J, Dobryansky M, Levine JP, Gurtner GC. Quantitative and reproducible murine model of excisional wound healing. *Wound Repair Regen*. 2004 Aug;12(4):485–92.
19. El-Attrouny MM, Iraqi MM, Sabike II, Abdelatty AM, Moustafa MM, Badr OA. Comparative evaluation of growth performance, carcass characteristics and timed series gene expression profile of GH and IGF-1 in two Egyptian indigenous chicken breeds versus Rhode Island Red. *J Anim Breed Genet*. 2020 Oct 24;
20. Abdelatty AM, Badr O a. M, Mohamed SA, Khattab MS, Dessouki SM, Farid O a. A, et al. Long term conjugated linoleic acid supplementation modestly improved growth performance but induced testicular tissue apoptosis and reduced sperm quality in male rabbit. *PLoS One*. 2020;15(1):e0226070.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001 Dec;25(4):402–8.
22. Zhao Y, Xu J, Le VM, Gong Q, Li S, Gao F, et al. EpCAM Aptamer-Functionalized Cationic Liposome-Based Nanoparticles Loaded with miR-139-5p for Targeted Therapy in Colorectal Cancer. *Mol Pharm*. 2019 Nov 4;16(11):4696–710.
23. Vasamsetti SB, Coppin E, Zhang X, Florentin J, Koul S, Götberg M, et al. Apoptosis of hematopoietic progenitor-derived adipose tissue-resident macrophages contributes to insulin resistance after myocardial infarction. *Sci Transl Med*. 2020 Jul 22;12(553).
24. Yue F, Bi P, Wang C, Li J, Liu X, Kuang S. Conditional Loss of Pten in Myogenic Progenitors Leads to Postnatal Skeletal Muscle Hypertrophy but Age-Dependent Exhaustion of Satellite Cells. *Cell Rep*. 2016 Nov 22;17(9):2340–53.
25. Shawber CJ, Brown-Grant D-A, Wu T, Kitajewski JK, Douglas NC. Dominant-negative inhibition of canonical Notch signaling in trophoblast cells does not disrupt placenta formation. *Biol Open*. 2019 Apr 16;8(4).
26. Roggia MF, Imai H, Shiraya T, Noda Y, Ueta T. Protective role of glutathione peroxidase 4 in laser-induced choroidal neovascularization in mice. *PLoS One*. 2014;9(6):e98864.
27. Ngamsri K-C, Jans C, Putri RA, Schindler K, Gamper-Tsigaras J, Eggstein C, et al. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation. *Front Immunol*. 2020;11:407.
28. Yashpal NK, Li J, Wheeler MB, Wang R. Expression of  $\beta$ 1 integrin receptors during rat pancreas development—sites and dynamics. *Endocrinology*. 2005 Apr;146(4):1798–807.
29. Badr O a. M, El-Shawaf IIS, El-Garhy H a. S, Moustafa MMA, Ahmed-Farid OA. The potent therapeutic effect of novel cyanobacterial isolates against oxidative stress damage in redox rats. *J Appl Microbiol*. 2019 Apr;126(4):1278–89.
30. Suvarna SK, Layton C, Bancroft JD. Bancroft's theory and practice of histological techniques [Internet]. 2019 [cited 2021 Feb 26]. Available from:

<https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20150001435>

31. Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. *Stem Cells Int.* 2012;2012:975871.
32. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier/Saunders; 2005.
33. Yang R, Liu F, Wang J, Chen X, Xie J, Xiong K. Epidermal stem cells in wound healing and their clinical applications. *Stem Cell Res Ther.* 2019 Jul 29;10(1):229.
34. Yang R, Wang J, Chen X, Shi Y, Xie J. Epidermal Stem Cells in Wound Healing and Regeneration. *Stem Cells Int.* 2020;2020:9148310.
35. Yang R-H, Qi S-H, Shu B, Ruan S-B, Lin Z-P, Lin Y, et al. Epidermal stem cells (ESCs) accelerate diabetic wound healing via the Notch signalling pathway. *Biosci Rep.* 2016 Aug;36(4).
36. Zhou X, Li G, Wang D, Sun X, Li X. Cytokeratin expression in epidermal stem cells in skin adnexal tumors. *Oncol Lett.* 2019 Jan;17(1):927–32.
37. Balint K. Activation of Notch1 signaling is required for -catenin-mediated human primary melanoma progression. *Journal of Clinical Investigation.* 2005 Nov 1;115(11):3166–76.
38. Chigurupati S, Arumugam TV, Son TG, Lathia JD, Jameel S, Mughal MR, et al. Involvement of Notch Signaling in Wound Healing. Hotchin N, editor. *PLoS ONE.* 2007 Nov 14;2(11):e1167.
39. Akil A, Gutiérrez-García AK, Guenter R, Rose JB, Beck AW, Chen H, et al. Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective. *Front Cell Dev Biol.* 2021 Feb 16;9:642352.
40. Mack JJ, Iruela-Arispe ML. NOTCH regulation of the endothelial cell phenotype: Current Opinion in Hematology. 2018 May;25(3):212–8.
41. Kimball AS, Joshi AD, Boniakowski AE, Schaller M, Chung J, Allen R, et al. Notch Regulates Macrophage-Mediated Inflammation in Diabetic Wound Healing. *Front Immunol.* 2017 Jun 1;8:635.
42. Kofler NM, Shawber CJ, Kangsamaksin T, Reed HO, Galatioto J, Kitajewski J. Notch Signaling in Developmental and Tumor Angiogenesis. *Genes & Cancer.* 2011 Dec 1;2(12):1106–16.
43. Miloudi K, Oubaha M, Ménard C, Dejda A, Guber V, Cagnone G, et al. NOTCH1 signaling induces pathological vascular permeability in diabetic retinopathy. *Proc Natl Acad Sci USA.* 2019 Mar 5;116(10):4538–47.
44. Caiado F, Real C, Carvalho T, Dias S. Notch Pathway Modulation on Bone Marrow-Derived Vascular Precursor Cells Regulates Their Angiogenic and Wound Healing Potential. Cordes N, editor. *PLoS ONE.* 2008 Nov 18;3(11):e3752.
45. Suchting S, Freitas C, le Noble F, Benedito R, Bréant C, Duarte A, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. *Proc Natl Acad Sci U S A.* 2007 Feb 27;104(9):3225–30.
46. Zhang C, Zhu Y, Lu S, Zhong W, Wang Y, Chai Y. Platelet-Rich Plasma with Endothelial Progenitor Cells Accelerates Diabetic Wound Healing in Rats by Upregulating the Notch1 Signaling Pathway.

- Journal of Diabetes Research. 2019 Aug 28;2019:1–12.
47. Huang Y-W, Zhu Q-Q, Yang X-Y, Xu H-H, Sun B, Wang X-J, et al. Wound healing can be improved by (-)-epigallocatechin gallate through targeting Notch in streptozotocin-induced diabetic mice. *FASEB J*. 2019 Jan;33(1):953–64.
  48. Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa A-R, Fernandes A-C, et al. Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. *PLoS One*. 2012;7(1):e29863.
  49. Yang JM, Ryu J, Kim I, Chang H, Kim I-K. Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice. *Adv Wound Care (New Rochelle)*. 2020 Nov;9(11):591–601.
  50. Motegi S, Ishikawa O. Mesenchymal stem cells: The roles and functions in cutaneous wound healing and tumor growth. *Journal of Dermatological Science*. 2017 May;86(2):83–9.
  51. Chang C, Yan J, Yao Z, Zhang C, Li X, Mao H-Q. Effects of Mesenchymal Stem Cell-Derived Paracrine Signals and Their Delivery Strategies. *Adv Healthc Mater*. 2021 Jan 12;e2001689.
  52. Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. *Stem Cell Res Ther*. 2010 Sep 24;1(4):30.
  53. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. *Am J Pathol*. 2004 Jun;164(6):1935–47.
  54. Li S, Zhou B, Han Z. Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia: A comparison between CD34+ and CD34- mononuclear cells. *Thromb Haemost*. 2006;95(02):301–11.
  55. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. *Stem Cells*. 2011 Jan;29(1):5–10.
  56. Suh W, Kim KL, Kim J-M, Shin I-S, Lee Y-S, Lee J-Y, et al. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization. *Stem Cells*. 2005 Dec;23(10):1571–8.
  57. Irons RF, Cahill KW, Rattigan DA, Marcotte JH, Fromer MW, Chang S, et al. Acceleration of diabetic wound healing with adipose-derived stem cells, endothelial-differentiated stem cells, and topical conditioned medium therapy in a swine model. *Journal of Vascular Surgery*. 2018 Dec;68(6):115S-125S.
  58. Xie J, Wang W, Si J-W, Miao X-Y, Li J-C, Wang Y-C, et al. Notch signaling regulates CXCR4 expression and the migration of mesenchymal stem cells. *Cell Immunol*. 2013 Jan;281(1):68–75.
  59. Williams CK, Segarra M, Sierra MDLL, Sainson RCA, Tosato G, Harris AL. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells. *Cancer Res*. 2008 Mar 15;68(6):1889–95.
  60. Dong Y, Jesse AM, Kohn A, Gunnell LM, Honjo T, Zuscik MJ, et al. RBPj-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. *Development*. 2010 May 1;137(9):1461–71.

61. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. *Nat Med.* 2008 Mar;14(3):306–14.
62. Vujovic S, Henderson SR, Flanagan AM, Clements MO. Inhibition of gamma-secretases alters both proliferation and differentiation of mesenchymal stem cells. *Cell Prolif.* 2007 Apr;40(2):185–95.
63. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. *Stem Cells.* 2007 Oct;25(10):2648–59.
64. li M, Takeshita K, Ibusuki K, Luedemann C, Wecker A, Eaton E, et al. Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. *Circulation.* 2010 Mar 9;121(9):1104–12.

## Figures





Figure 1

Schematic representation of experimental design



**Figure 2**

(A) An inverted microscope micrograph from primary culture of mesenchymal stem cells. (B) Fluorescent microscopic image demonstrating fluorescence of MSCs labeled with GFP two weeks after implantation. (C) CD105 immunoexpression in cutaneous tissues 2 weeks post-transplantation of MSCs (arrow). (D) Flow cytometry analysis of surface antigens of MSCs; CD45: 0.2%, CD90: 90.38% and CD105: 99.82%. (E) Osteogenesis differentiation stained with von Kossa stain. (F) Adipogenesis differentiation stained with

Oil Red O stain. (G) Chondrogenesis differentiation stained with Alcian blue stain. (g&h) Immuno-expression of CD105 in group IV&V. (i) Mean area percentage of CD105 expression in the different experimental groups.





Figure 3


photograph represents wound contraction rate. Data are expressed as mean±SE. \*\* significant compared to control group at p<0.01, \$\$ significant compared to Sham group at p<0.01, ## significant compared to diabetic group at p<0.01, ££ significant compared to group IV and V at p<0.01, ~~ significant compared to group IV at p<0.01.



**Figure 4**

The H&E-stained skin sections revealed that PRP+ADSCs-treatment accelerate the diabetic wound healing: (a) group I showed normal epidermis (E) and dermis with its papillary(P) and reticular(R) layers. (b): group IIa showed thin epidermis(E) with inflammatory cell infiltration(i) in papillary layer(P). (c): group IIb showed near normal epidermis (E) and dermis with its papillary(P) and reticular layers(R). (d &e): group III showed interrupted epidermis with & disorganized keratinocytes with vacuolated cytoplasm (V)

& absence of keratin, wound beds were covered by a single layer of squamous cells (curved arrow). Dermis showed massive inflammatory infiltration, and minimal fine collagen deposition (arrow) with areas of deficient collagen deposition (asterisk). The reticular (R) layer has thick collagen bundles (bold arrow). (f-k) all treated groups: showed intact epidermis (E) with keratohyalin granules and keratin with papillary (P) layer showed fine collagen fibers (arrow), and blood capillaries (arrowhead). The reticular (R) layer has thick collagen bundles (bold arrow). (l) Epidermal thickness of the different experimental groups. Data are expressed as median (maximum and minimum), \*\* significant compared to control group at  $p < 0.01$ , \$\$ significant compared to Sham group at  $p < 0.01$ , ## significant compared to diabetic group at  $p < 0.01$ , ££ significant compared to group IV and V at  $p < 0.01$ , ~ significant compared to group V at  $p < 0.05$ , ~~ significant compared to group IV at  $p < 0.01$ .



**Figure 5**

Masson's trichrome staining of cutaneous tissue was performed to assess dermal collagen different experimental groups (a-k), as there was fine interlacing fibers (arrow) in the papillary (P) layer, and thick, irregular blue bundles (bold arrow parallel) to the surface in the reticular (R) layer. In group III there were areas of deficient collagen deposition are seen beneath the epidermis (asterisk). (l) Mean area percentage of dermal collagen. Data are expressed as median (maximum and minimum), \*\* significant compared to

control group at  $p < 0.01$ , \* significant compared to control group at  $p < 0.05$ , \$\$ significant compared to Sham group at  $p < 0.01$ , # significant compared to diabetic group at  $p < 0.05$ , ## significant compared to diabetic group at  $p < 0.01$ , ££ significant compared to group IV and V at  $p < 0.01$ , ~ significant compared to group V at  $p < 0.05$ , ~~ significant compared to group IV at  $p < 0.01$ .





Figure 6

Representative photomicrographs of PCNA immune stained sections showing the basal keratinocytes of the different experimental groups (a-k). All groups showed moderate reaction except group IIb & VI, showed intense reaction of PCNA (c, j & k). (l) Mean area percentage of PCNA expression in the different experimental groups. Data are expressed as median (maximum and minimum), \*\* significant compared to control group at  $p < 0.01$ , \$\$ significant compared to Sham group at  $p < 0.01$ , ## significant compared to diabetic group at  $p < 0.01$ , ££ significant compared to group IV and V at  $p < 0.01$ .





Figure 7


Representative photomicrographs of CD31 immune stained sections showing the endothelial cells of the blood capillaries of different experimental groups (a-k). (a) Group I: showing a moderate reaction (arrowhead) in the capillaries. (b) Group IIa: showing a weak reaction (arrowhead) in few capillaries. (c) Group IIb: strong reaction (arrowhead) in many capillaries. (d & e) Groups III a & b: negative reaction (arrowhead) in the capillaries. (f) Group IVa: showing a moderate reaction (arrowhead) in some capillaries. (g) Group IVb: showing a strong reaction in the capillaries (h) Group Va: showing a mild reaction in the capillaries. (i) Group Vb: showing a moderate reaction in the capillaries. (j & k) Groups VI a & b: showing a strong reaction in both days with an increase in the number of capillaries seen on the 14th day. (l) Vascular area density/ vascular index in the different experimental groups. Data are expressed as median (maximum and minimum), \*\* significant compared to control group at  $p < 0.01$ , \$\$ significant compared to Sham group at  $p < 0.01$ , ## significant compared to diabetic group at  $p < 0.01$ , ~ significant compared to group V at  $p < 0.05$ , ~~ significant compared to group IV at  $p < 0.01$ .



**Figure 8**

Effect of PRP and/or ADSCs on gene expression of (a) Notch1, (b) Dll4, (c) Hes 1, (d) Jag 1, (e) Hey 1, (f) VEGF, (g) EPSCm, (h) SDF-1 normalized to GAPDH and expressed as fold of the control. Data are expressed as mean±SE, \*\* significant compared to control group at p<0.01, \* significant compared to control group at p<0.05, \$\$ significant compared to Sham group at p<0.01, # significant compared to

diabetic group at  $p < 0.05$ , ## significant compared to diabetic group at  $p < 0.01$ , ££ significant compared to group IV and V at  $p < 0.01$ , ~ significant compared to group IV at  $p < 0.05$ .



**Figure 9**

(a) Western blot analysis for measuring Notch1, Hes 1 and Jag 1. GAPDH was used for normalization. (b), (c), (d) The intensity of immunoreactivity for selected proteins was quantified by densitometry. Data are expressed as mean±SE. \* significant compared to control group at  $p < 0.05$ , \*\* significant compared to control group at  $p < 0.01$ , \$\$ significant compared to Sham group at  $p < 0.01$ , # significant compared to diabetic group at  $p < 0.05$ , ## significant compared to diabetic group at  $p < 0.01$ , ££ significant compared to group IV and V at  $p < 0.01$ , ~ significant compared to group IV at  $p < 0.05$ .